Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Appropriate Antibiotic Use for Acute Otitis Media
Your Article Summary
See Latest ArticlesThe diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer
Cancer, 06/25/09
Kao J et al. - In a study to investigate the clinical value of a follow-up program incorporating serial 18F-fluorodeoxyglucose-positron emission tomography integrated with computed tomography (PET/CT) in detection of recurrent disease in pts with head and neck cancer (HNC), it was shown that although post-therapy follow-up using PET/CT is reportedly associated with a high false-positive rate in the irradiated head and neck, PET/CT appears to be a highly sensitive technique for detection of recurrent disease. Negative PET/CT results within 6 mos of completion of RT offer significant prognostic value.
Methods- 240 PET/CT scans were reviewed in 80 pts with HNC who were treated with radiotherapy (RT).
- All pts were followed with clinical examination, PET/CT, and correlative imaging for a minimum of 11 mos.
- Sensitivity, specificity, and positive and negative predictive values of PET/CT-based follow-up for detecting locoregional recurrence were 92%, 82%, 42%, and 98%, respectively.
- Corresponding values for distant metastases or second primary tumors were 93%, 96%, 81%, and 98%, respectively.
- 8 pts (10%) developed disease recurrences or second primary tumors that were amenable to salvage surgery with negative surgical margins.
- 2-yr progression-free survival and 2-yr overall survival rates were significantly different between pts who had a negative and those with a positive PET/CT result within 6 mos of completion of RT (93% vs 30% and 100% vs 32%, respectively).
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial
Journal of Clinical Oncology, 11/25/09
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/12/09
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Today in Radiology/Diagnostics...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/12/09
Nystagmus during Attacks of Vestibular Migraine: An Aid in Diagnosis
Audiology & Neuro-Otology, 11/05/09
Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma
Annals of Oncology, 11/19/09
Article Search
Sponsor